SCHEMBL4486124

SCHEMBL4486124

CS(=O)(=O)c1ccccc1-c1ccc(N2CCCC(NC(=O)C(=O)N3CCOCC3)C2=O)c(F)c1

nearest known ligand 0.68

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 6/20 0.68
FPR1 P21462 4/20 0.68
F10 P00742 14/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4485882 0.92 FPR2 (0.69) FPR2FPR1F10
SCHEMBL4486127 0.88 F10 (0.65) FPR2FPR1F10
SCHEMBL18955218 0.86 FPR2 (0.77) FPR2FPR1F10
SCHEMBL20555885 0.86 FPR2 (0.77) FPR2FPR1F10
SCHEMBL4681099 0.83 F10 (0.85) FPR2FPR1F10
SCHEMBL4491905 0.82 FPR2 (0.71) FPR2FPR1F10
SCHEMBL30133742 0.82 F10 (0.72) FPR2FPR1F10
SCHEMBL4684779 0.82 F10 (0.85) FPR2FPR1F10
SCHEMBL30337924 0.82 F10 (0.72) FPR2FPR1F10
SCHEMBL18964514 0.82 F10 (0.72) FPR2FPR1F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7157470-B2 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-02 US claimed
US-7524863-B2 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-04-28 US disclosed
US-7157470-B2 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-02 US disclosed
US-20060247243-A1 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors SMALLHEER JOANNE M 2006-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247243-A1 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors TFPI, SPINT2, F5 FPR2 3867/4885FPR1 2550/4885F10 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.